Integrating smoking cessation treatment into online psychological care

Conditions

Smoking cessation treatment for patients with common mental illness Other

Taylor G, Jacobsen P, Blackwell A, Daryan S, Roy D, Duffy D, Hisler G, Sawyer K, Ainsworth B, Hiscock D, Papadakis S, Brown J, Munafò M, Aveyard P.

2025-12-05

10.2196/78424

Integrating Smoking Cessation Treatment Into Web-Based Usual Psychological Care for People With Common Mental Illness: Feasibility Randomized Controlled Trial (ESCAPE Digital) (Preprint)

Gemma Taylor, Pamela Jacobsen, Anna Blackwell, Shadi Daryan, Deborah Roy et al. (14 authors)

2025-06-02

10.2196/preprints.78424

IntEgrating Smoking Cessation treAtment into usual online Psychological care for people with common mEntal illness: Protocol for an online randomised feasibility and pilot study (ESCAPE digital).

Blackwell AKM, Daryan S, Roy D, Duffy D, Hisler G, Sawyer K, Ainsworth B, Richards D, Hiscock D, Papadakis S, Brown J, Munafò MR, Jacobsen P, Aveyard P, Taylor G.

2024-04-211 citations

10.1016/j.cct.2024.107541

Interventions

A two-armed, pragmatic, online, randomised, and controlled feasibility and pilot trial will be used to test the acceptability and feasibility of an online smoking cessation intervention, and the trial

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Adult (aged 18+ years), 2. Self-reported regular (daily or non-daily) smokers 3. Eligible for SilverCloud treatment, according to therapists/psychological wellbeing practitioners 4. Comorbidities are allowed

Exclusion criteria

Exclusion criteria: 1. Aged under 18 2. Non-smoker 3. Not eligible for SilverCloud treatment

Design outcomes

Primary

Measure	Time frame
Self-reported quit attempt (at least 24 hours quit) measured using an online questionnaire at 2, 4, 6, 8 and 10 weeks, and 3-month follow up	—

Secondary

Measure	Time frame
1. Engagement with, and completion of, the online smoking cessation and mental health programmes measured using SilverCloud data over 12 weeks. 2. Self-reported smoking cessation medicine and e-cigarette use measured using an online questionnaire at baseline, 2, 4, 6, 8 and 10 weeks, and 3 and 6 months follow up. 3. Depression and anhedonia (Patient Health Questionnaire; PHQ-9) measured using SilverCloud data at baseline and at 2, 4, 6, 8 and 10 weeks, and 3 and 6 months follow up by online questionnaire 4. Anxiety (General Anxiety Disorder Questionnaire; GAD-7) measured using SilverCloud data at baseline and at 2, 4, 6, 8 and 10 weeks, and 3 and 6 months follow up by online questionnaire 5. Quality of health measured using an online questionnaire at 3 and 6 months follow up 6. Self-reported smoking cessation measured using an online questionnaire at the 3-month follow-up (4-weeks abstinent) and 6-month follow-up (prolonged 12-week abstinence) 7. Saliva cotinine (i.e., 15 nanograms per millilitre), or salivary anabasine (<1ng/ml) if using nicotine, measured to confirm smoking abstinence, using saliva sample testing kits that will be posted to participants with a pre-paid envelope to send to ACM Bioanalytical Services (https://www.acmgloballab.com/bioanalytical-services) laboratory for testing at the 3 and 6-month follow-ups (for those reporting cessations) 8. Patient acceptability and satisfaction with the intervention measured using an online questionnaire and qualitative interview conducted remotely online or by telephone (intervention arm only) at the 6-month follow-up 9. Patient acceptability with the trial procedures measured using an online questionnaire at the 6-month follow-up 9. Clinician acceptability of the intervention measured using an online questionnaire and qualitative interview conducted remotely online or by telephone at the end of the trial 10. Engagement with the mental health treatment service (e.g., number of attended/missed appointments, di	—

Measure

Time frame

1. Engagement with, and completion of, the online smoking cessation and mental health programmes measured using SilverCloud data over 12 weeks. 2. Self-reported smoking cessation medicine and e-cigarette use measured using an online questionnaire at baseline, 2, 4, 6, 8 and 10 weeks, and 3 and 6 months follow up. 3. Depression and anhedonia (Patient Health Questionnaire; PHQ-9) measured using SilverCloud data at baseline and at 2, 4, 6, 8 and 10 weeks, and 3 and 6 months follow up by online questionnaire 4. Anxiety (General Anxiety Disorder Questionnaire; GAD-7) measured using SilverCloud data at baseline and at 2, 4, 6, 8 and 10 weeks, and 3 and 6 months follow up by online questionnaire 5. Quality of health measured using an online questionnaire at 3 and 6 months follow up 6. Self-reported smoking cessation measured using an online questionnaire at the 3-month follow-up (4-weeks abstinent) and 6-month follow-up (prolonged 12-week abstinence) 7. Saliva cotinine (i.e., 15 nanograms per millilitre), or salivary anabasine (<1ng/ml) if using nicotine, measured to confirm smoking abstinence, using saliva sample testing kits that will be posted to participants with a pre-paid envelope to send to ACM Bioanalytical Services (https://www.acmgloballab.com/bioanalytical-services) laboratory for testing at the 3 and 6-month follow-ups (for those reporting cessations) 8. Patient acceptability and satisfaction with the intervention measured using an online questionnaire and qualitative interview conducted remotely online or by telephone (intervention arm only) at the 6-month follow-up 9. Patient acceptability with the trial procedures measured using an online questionnaire at the 6-month follow-up 9. Clinician acceptability of the intervention measured using an online questionnaire and qualitative interview conducted remotely online or by telephone at the end of the trial 10. Engagement with the mental health treatment service (e.g., number of attended/missed appointments, di

—

Countries

England, United Kingdom

Contacts

Public ContactDeborah Roy

smokingstudy@bath.ac.uk+44 (0)1225 385091

Outcome results

None listed